Modality
Gene Editing
MOA
USP1i
Target
EZH2
Pathway
Ferroptosis
AsthmaEwing SarcomaCervical Ca
Development Pipeline
Preclinical
May 2021
→ May 2030
PreclinicalCurrent
NCT08316834
2,266 pts·Ewing Sarcoma
2021-05→2030-05·Completed
2,266 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-034.1y awayInterim· Ewing Sarcoma
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Complet…
Catalysts
Interim
2030-05-03 · 4.1y away
Ewing Sarcoma
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08316834 | Preclinical | Ewing Sarcoma | Completed | 2266 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| ITO-535 | iTeos | NDA/BLA | MDM2 | |
| Tezeratamab | Prime Medicine | Phase 3 | CGRP |